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Abstract
Background: Women harboring BRCA1/2 germline mutations have high lifetime risk of developing breast/ovarian
cancer. The recommendation to pursue BRCA1/2 testing is based on patient’s family history of breast/ovarian
cancer, age of disease-onset and/or pathologic parameters of breast tumors. Here, we investigated if diagnosis of
triple-negative breast cancer (TNBC) independently increases risk of carrying a BRCA1/2 mutation in Pakistan.
Methods: Five hundred and twenty-three breast cancer patients including 237 diagnosed ≤ 30 years of age and
286 with a family history of breast/ovarian cancer were screened for BRCA1/2 small-range mutations and large
genomic rearrangements. Immunohistochemical analyses were performed at one center. Univariate and multiple
logistic regression models were used to investigate possible differences in prevalence of BRCA1/2 mutations
according to patient and tumor characteristics.
Results: Thirty-seven percent of patients presented with TNBC. The prevalence of BRCA1 mutations was higher
in patients with TNBC than non-TNBC (37 % vs. 10 %, P < 0.0001). 1 % of TNBC patients were observed to have
BRCA2 mutations. Subgroup analyses revealed a larger proportion of BRCA1 mutations in TNBC than non-TNBC
among patients 1) diagnosed at early-age with no family history of breast/ovarian cancer (14 % vs. 5 %, P = 0.
03), 2) diagnosed at early-age irrespective of family history (28 % vs. 11 %, P = 0.0003), 3) had a family history of
breast cancer (49 % vs. 12 %, P < 0.0001), and 4) those with family history of breast and ovarian cancer (81 % vs.
28 %, P = 0.0005). TNBC patients harboring BRCA1 mutations were diagnosed at a later age than non-carriers
(median age at diagnosis: 30 years (range 22–53) vs. 28 years (range 18–67), P = 0.002). The association between
TNBC status and presence of BRCA1 mutations was independent of the simultaneous consideration of family
phenotype, tumor histology and grade in a multiple logistic regression model (Ratio of the probability of carrying
BRCA1/2 mutations for TNBC vs. non-TNBC 4.23; 95 % CI 2.50–7.14; P < 0.0001).
Conclusion: Genetic BRCA1 testing should be considered for Pakistani women diagnosed with TNBC.
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Background
Women carrying a pathogenic germline mutation in
the BRCA1 and BRCA2 genes have an increased life-
time risk of developing breast, ovarian, and several
other cancers [1]. The identification of women harbor-
ing mutations in these genes is clinically important and
has a significant socio-cultural impact. A major chal-
lenge faced by physicians is to identify most appropriate
candidates for genetic BRCA1/2 testing since the cost
of comprehensive genetic testing can be high and only
3 % of all breast cancers are attributed to BRCA1/2
germline mutations.
The decision to offer genetic testing to a breast can-
cer patient is currently based on family history of
breast/ovarian cancer and age of disease onset. Several
prediction models, which consider age of onset and
family history of cancer, can be used to estimate the
prior probability of having a BRCA1 or BRCA2 muta-
tion [2]. In addition, histopathological tumor parame-
ters can be considered to help predict the presence of a
mutation.
Triple negative breast cancer (TNBC) is defined by
the absence of estrogen receptor (ER), progesterone re-
ceptor (PR), human epidermal growth factor receptor 2
(HER2) and accounts for 12–15 % of all invasive breast
cancer [3]. It occurs most frequently in young women
and African-Americans. In Pakistan, 10-year outcome
analysis of 636 breast cancer patients registered at a
tertiary-care cancer center (Shaukat Khanum Memorial
Cancer Hospital and Research Centre - SKMCH & RC)
showed that 30.5 % (194/636) of the cases had TNBC;
and majority (56.2 %) had their diagnosis made at less
than 40 years of age [4]. Patients with TNBC are known
to have unfavorable survival compared to patients with
other breast cancer subtypes [5].
A large proportion of tumors in women with BRCA1
mutations are associated with the TNBC phenotype
[6]. BRCA1/2 mutations have been identified with fre-
quencies varying from 9.4 to 15.4 % in unselected, 17.4
to 49.1 % in younger age and 11.6 to 62 % in high risk
patients with TNBC [7–15]. Studies reporting the fre-
quency of BRCA1/2 mutations in TNBC patients from
Asia have had several deficiencies including small
population size [16–18], restriction of analysis to
BRCA1 gene [19, 20] and evaluation limited to small-
range mutations [16, 21, 22]. In order to determine the
utility of genetic testing for BRCA1 and BRCA2 germ-
line mutations for women with TNBC in Pakistan, we
comprehensively screened both genes for small-range
mutations as well as large genomic rearrangements in
a group of 523 breast cancer patients who were se-
lected based on early-age of disease onset or family
history of breast/ovarian cancer, including 192 patients
diagnosed with TNBC.
Methods
Study subjects
Index patients included in this study had a diagnosis
of primary invasive breast cancer and were selected
based on the following criteria: 1) one female breast
cancer diagnosed ≤ 30 years of age; 2) two or more
first- or second-degree (through a male) female rela-
tives diagnosed with breast cancer with at least one di-
agnosed ≤ 50 years of age; or 3) at least one female
breast cancer and one ovarian cancer at any age. A
total of 573 women recruited at the SKMCH & RC in
Lahore, Pakistan, from June 2001 to February 2014
fulfilled these criteria. Blood samples were obtained
from all patients for the isolation of genomic DNA.
Clinical, histopathologic and risk factor data were col-
lected from all study participants. Fifty patients were
excluded from the study. Reasons for exclusion are de-
tailed in Fig. 1.
The study was approved by the Ethical Review Board
of the SKMCH & RC. All study participants signed in-
formed written consent.
BRCA1/2 screening for small-range mutations and large
genomic rearrangements
Genomic DNA was isolated as previously described
[23]. One hundred and twenty-one cases comprehen-
sively screened for BRCA1 (Genbank accession number
U14680.1) and BRCA2 (Genbank accession number
U43746.1) small-range mutations using protein-truncation
test (PTT), single-strand conformational polymorphism
analysis (SSCP) and denaturing high-performance liquid
chromatography (DHPLC) analysis followed by DNA se-
quencing of variant fragments, and 26 BRCA1/2 mutations
was described in an earlier report [23] (primer sequences
are available upon request). When available, a mutation
positive control was included in each set of PTT, SSCP and
DHPLC analyses. A description of the BRCA1/2 screening
methods is given in Supplementary methods (Additional
file 1). The remaining 402 cases recruited subsequently
were screened for BRCA1/2 small-range mutations
using DHPLC and DNA sequencing analyses. Of these,
295 cases were previously described [24]. All patients
negative for small-range BRCA1/2 mutations were fur-
ther screened for large genomic rearrangements. Multi-
plex ligation-dependent probe amplification (MLPA)
analysis was performed using probe mix P003 and
P087 for BRCA1 and probe mix P045 for BRCA2
according to the manufacturer’s instructions (MRC
Holland, Amsterdam, The Netherlands).
Immunohistochemical (IHC) analysis
Formalin-fixed paraffin-embedded (FFPE) blocks were
retrieved from the pathology department; blocks were
not available for 38 patients (Fig. 1). Tumor grade was
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assigned using the Nottingham Histologic Score. IHC
analysis of ER, PR and HER2 expression was performed
using standard methods [25]. Slides were interpreted by
a trained breast pathologist who was blinded to
BRCA1/2 mutation status. Tumors were considered
negative for ER and PR if < 1 % of tumor cells demon-
strated positive nuclear staining. Tumors were consid-
ered negative for HER2 if IHC score was 0 or 1+. Cases
with IHC score 2+ were further subjected to fluorescence
in situ hybridization (FISH) using the PathVysion® HER2
DNA probe kit (Abbott Laboratories, Abbott Park, IL).
Tumors with a HER2/CEP17 ratio of > 2.2 and tumors
with IHC score 3+ were considered positive.
Statistical analysis
The comparison of the distribution of clinical and histo-
pathological characteristics between BRCA1/2 carriers
and non-carriers was done using Fisher’s exact test for
categorical variables and the Wilcoxon rank-sum test for
quantitative variables. Univariate and multiple logistic
regression models were used to investigate possible
differences in the prevalence of BRCA1/2 mutations ac-
cording to patient and tumor characteristics. All statis-
tical tests were two sided. Results were deemed
statistically significant if the P value was 0.05 or less. All
statistical computations were done using StatXact 4 for
Windows (Cytel Inc., Cambridge, USA), SAS version 9.3
and R, version 2.1.
Results
Clinical characteristics of the study participants and
histopathologic parameters of tumors according to
TNBC status
In total 523 unrelated Pakistani women diagnosed with
primary invasive breast cancer were included in the
study. Of these, 45.3 % were diagnosed at young age
(≤ 30 years) and 54.7 % reported a positive family his-
tory of breast/ovarian cancer. IHC analysis of ER, PR,
and HER2 expression showed that 36.7 % of the pa-
tients presented with TNBC. Compared to non-TNBC
patients, women with TNBC had an earlier age of diag-
nosis (31.6 years (range 18–67) and 35.6 years (range
Women diagnosed with invasive primary 
BC (<30 years of age) or familial BC/OC
in the time period from 
June 2001 to February 2014
(n = 573)
Screening for BRCA1/2
small-range mutations and 
large genomic rearrangements
(n = 567)
In-person interview, blood collection and 
DNA extraction
(n = 573)
Excluded:
No DNA yield(n = 6)
Pathology data collection and IHC 
analysis for ER/PR/HER2 expression
(n = 567)
BC patients included in the study
(n = 523)
1 early-onset BC (<30 years) (n = 237)
Familial BC (n = 235)
Familial BC and OC (n = 51)
TNBC
(n = 192)
Non-TNBC
(n = 331)
Excluded:
Pathological specimen not 
available
(n = 38)
ER/PR negative, HER2 status 
unknown
(n = 6)
Fig. 1 Description of the study participants. BC, breast cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; OC, ovarian
cancer; PR, progesterone receptor; TNBC, triple-negative breast cancer
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19–73), respectively; P < 0.0001, Wilcoxon rank-sum
test), were more often premenopausal (91.1 % vs.
80.7 %, P = 0.002) and of Punjabi ethnicity (79.5 % vs.
69.2 %, P = 0.03). TNBC tumors were observed to have
greater propensity for invasive ductal carcinoma com-
pared to non-TNBC (96.4 % vs. 89.4 %, P = 0.004),
higher tumor grade 3 (88.8 % vs. 62.9 %, P < 0.0001),
and lymph node negativity (53.9 % vs. 32.5 %, P <
0.0001). Selected clinical and histopathologic charac-
teristics of the study participants by TNBC status are
shown in Table 1.
BRCA1/2 mutation prevalence in patients with TNBC
and non-TNBC
The complete coding regions of the BRCA1 and BRCA2
genes were screened for small-range mutations and large
genomic rearrangements in all 523 breast cancer pa-
tients. Overall, 125 cases with deleterious mutations
were identified, of these, 105 occurred in BRCA1 (84 %)
and 20 (16 %) in BRCA2 (Table 2). BRCA1 mutations
were more frequent in patients with TNBC than in those
with non-TNBC (37 % vs. 10.3 %, P < 0.0001). Majority
of the mutations in patients with TNBC, 97.3 % (71/73),
were detected in BRCA1; 2.7 % (2/73) had mutations in
BRCA2 (P < 0.0001) (Additional file 2: Table S1). The
corresponding percentage for BRCA1 and BRCA2 muta-
tions in non-TNBC cases was 65.4 % (34/52) and 34.6 %
(18/52) (P = 0.04).
In this study, patients with TNBC harboring a BRCA1
mutation (n = 71) were older than BRCA1/2 non-carriers
(n = 119) with mean age of diagnosis 32.9 years (range
22–53) and 30.9 years (range 18–67), respectively (P =
0.002, Exact Wilcoxon rank-sum test). The mean age for
non-TNBC patients was 33.5 years (range 21–72) for
BRCA1 carriers (n = 34), 36.8 (range 25–54) for BRCA2
carriers (n = 18) and 35.7 (range 19–73) for non-carriers
(n = 279).
Subgroup analysis by family phenotype, age of diagnosis,
and ethnicity
Prevalence of BRCA1/2 mutations in patients with
TNBC and non-TNBC distributed by family phenotype,
age of diagnosis, and ethnicity is detailed in Table 3.
Among patients with TNBC, BRCA1 mutations were
identified in 14.4 % of patients with early-onset disease
(≤ 30 years), 48.7 % of patients with familial breast can-
cer and in 80.8 % of patients with familial breast and
ovarian cancer. These frequencies were higher than the
corresponding frequencies of 5.4, 12.0 and 28.0 % ob-
served in non-TNBC patients (P = 0.03, P < 0.0001 and
P = 0.0005, respectively). Mutations in BRCA2 were de-
tected in 2.6 % of patients with familial breast cancer
and were absent in those with early-onset disease and fa-
milial breast and ovarian cancer. Similar frequencies
Table 1 Selected clinical and pathological characteristics of the
523 Pakistani cases according to TNBC status
Parameters TNBC
(N = 192)
Non-TNBC
(N = 331)
Pa
n (%) n (%)
Age at diagnosis of BC (years)
Mean 31.6 35.6 < 0.0001b
Range 18–67 19–73
Family phenotype
1 early-onset BC (≤30 years) 90 (46.9) 147 (44.4) NSc
Familial BC 76 (39.6) 159 (48.0)
Familial BC and OC 26 (13.6) 25 (7.6)
Menopausal status
Premenopausal 174 (91.1) 267 (80.7) 0.002d
Postmenopausal 17 (8.9) 64 (19.3)
Unknown 1 0
Ethnicity
Punjabi 151 (79.5) 229 (69.2) 0.03e
Pathan 19 (10.0) 54 (16.3)
Others 20 (10.5) 48 (14.5)
Unknown 2 0
Histology
Ductal 185 (96.4) 294 (89.4) 0.004f
Lobular 1 (0.5) 15 (4.6)
Mixedg 2 (1.0) 11 (3.3)
Mucinous 0 6 (1.8)
Metaplastic 2 (1.0) 3 (0.9)
Medullary 2 (1.0) 0
Unknown 0 2
Tumor size
pT1 30 (20.3) 71 (26.9) NSh
pT2 91 (61.5) 147 (55.7)
pT3 24 (16.2) 44 (16.7)
pT4 3 (2.0) 2 (0.7)
Unknown 44 67
Tumor grade (Nottingham)
1 0 5 (1.6) < 0.0001i
2 20 (11.2) 111 (35.5)
3 158 (88.8) 197 (62.9)
Unknown 14 18
Lymph node status
Positive 83 (46.1) 212 (67.5) < 0.0001j
Negative 97 (53.9) 102 (32.5)
Unknown 12 17
P values marked in bold are statistically significant
BC breast cancer, NS non-significant, OC ovarian cancer, TNBC triple-negative
breast cancer. aFisher’s exact test. bWilcoxon rank-sum test. cEarly-onset vs.
familial BC and early-onset vs. familial BC and OC. dPremenopausal vs. post-
menopausal. ePunjabi vs. Pathan. fDuctal vs. others. gIncluding ductal carcin-
omas with lobular and mucinous features. hpT1 vs. pT2+. iGrade 1, 2 vs. 3. jLymph
node positive vs. negative
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were observed in non-TNBC patients; 4.1 % in patients
with early-onset disease, 6.9 % in those with familial breast
cancer, and 4.0 % in patients with familial breast and ovar-
ian cancer (P = 0.09, P = 0.73 and P = 1.0, respectively).
In this study, age appeared to have a marked influ-
ence on the BRCA1 mutation frequency in familial
breast/ovarian cancer patients diagnosed with TNBC.
In patients over 50 years of age, the frequency was
11.1 %. For younger patients the frequency was 58.5 %
for those ≤ age 30, 68.8 % for those between 31 and 40
years, and 55 % for those between 41 and 50 years. The
BRCA1 mutation frequency in the age subgroups 31–
40 and 41–50 years were higher in patients with TNBC
than those with non-TNBC (68.8 % vs. 15.2 %, P <
0.0001 and 55 % vs. 7 %, P < 0.0001). Higher BRCA1
mutation frequency was observed in early-onset breast
cancer patients regardless of family history of breast/
ovarian cancer (28.2 % vs. 11 %, P = 0.0003).
In this study, analysis by ethnicity showed that BRCA1
mutation frequency in patients with TNBC belonging to
the ethnic group of Punjabis, Pathans and other minor
ethnic groups was higher than observed in non-TNBC
patients (37.1 % vs. 12.2 %, P < 0.0001; 31.6 % vs. 5.6 %,
P = 0.01 and 40 % vs. 6.2 %, P = 0.003), respectively.
Results from logistic regression analysis
BRCA1/2 mutation carriers and non-carriers were diag-
nosed with breast cancer at similar age. Each additional
year at diagnosis translated into a 1 % lower risk of car-
rying BRCA1 mutations and a 1 % higher risk of har-
boring BRCA2 mutations, but differences did not reach
statistical significance (Ratio of the probability of carry-
ing BRCA1/2 mutations (RP) = 0.99; 95 % CI 0.97–1.01;
P = 0.34 and RP = 1.01; 95 % CI 0.97–1.05; P = 0.56), re-
spectively (Table 4). Patients with a family history of
breast cancer, and in particular patients with a family
history of breast and ovarian cancer, showed 237 and
1172 % increased risk of carrying BRCA1 mutations, re-
spectively, compared to women affected by early-onset
breast cancer (Global P < 0.0001) (corresponding RP =
3.37; 95 % CI 1.96–5.80; and RP = 12.72; 95 % CI 6.22–
Table 2 BRCA1/2 mutation frequencies in patients with TNBC
and non-TNBC
TNBC (N = 192) Non-TNBC (N = 331) Pa
Mutation status n (%) n (%)
Carriers 73 (38.0) 52 (15.7) < 0.0001b
BRCA1 71 (37.0) 34 (10.3) < 0.0001c
BRCA2 2 (1.0) 18 (5.4) NSd
Non-carriers 119 (62.0) 279 (84.3)
P values marked in bold are statistically significant
NS non-significant, TNBC triple-negative breast cancer
aFisher’s exact test. bCarriers vs. non-carriers. cBRCA1 carriers vs. non-carriers
dBRCA2 carriers vs. non-carriers
Table 3 BRCA1/2 mutation frequencies in patients with TNBC and non-TNBC, by age-at-diagnosis, family phenotype and ethnicity
Variables TNBC (N = 192) Non-TNBC (N = 331) Pa
No. of
cases
No. of mutations (%) in Non- No. of
cases
No. of mutations (%) in Non-
BRCA1 BRCA2 BRCA1/2 carriers BRCA1 BRCA2 BRCA1/2 carriers
Family phenotype
1 early-onset BC (≤ 30 years) 90 13 (14.4) 0 (0) 13 (14.4) 77 147 8 (5.4) 6 (4.1) 14 (9.5) 133 0.03
Familial BC 76 37 (48.7) 2 (2.6) 39 (51.3) 37 159 19 (12.0) 11 (6.9) 30 (18.9) 129 < 0.0001
Familial BC and OCb 26 21 (80.8) 0 (0) 21 (80.8) 5 25 7 (28.0) 1 (4.0) 8 (32.0) 17 0.0005
Age at diagnosis of familial BC/OC (years)
≤ 30 41 24 (58.5) 2 (4.9) 26 (63.4) 15 25 11 (44.0) 0 (0) 11 (44.0) 14 NS
31–40 32 22 (68.8) 0 (0) 22 (68.8) 10 59 9 (15.2) 6 (10.2) 15 (25.4) 44 < 0.0001
41–50 20 11 (55.0) 0 (0) 11 (55.0) 9 71 5 (7.0) 3 (4.2) 8 (11.3) 63 < 0.0001
> 50 9 1 (11.1) 0 (0) 1 (11.1) 8 29 1 (3.4) 3 (10.3) 4 (13.8) 25 NS
Early-onset BC (regardless of a family history of BC/OC)
≤ 30 years 131 37 (28.2) 2 (1.5) 39 (29.8) 92 172 19 (11.0) 6 (3.5) 25 (14.5) 147 0.0003
Ethnicity
Punjabi 151 56 (37.1) 2 (1.3) 58 (38.4) 93 229 28 (12.2) 9 (3.9) 37 (16.2) 192 < 0.0001
Pathan 19 6 (31.6) 0 (0) 6 (31.6) 13 54 3 (5.6) 4 (7.4) 7 (13.0) 47 0.01
Othersc 20 8 (40.0) 0 (0) 8 (40.0) 12 48 3 (6.2) 5 (10.4) 8 (16.7) 40 0.003
Unknown 2 1 (50.0) 0 (0) 1 (50) 1 0 0 0 0 0
P values marked in bold are statistically significant
BC breast cancer, NS non-significant, OC ovarian cancer, TNBC triple-negative breast cancer
aFisher’s exact test; BRCA1 carriers vs. non-carriers. bOnly female index cases affected with BC were included. cOther: minor ethnic groups including Urdu speaking,
Saraiki, Kashmiri, Balochi, Indian migratory, Sindhi, Gujrati, Persian speaking, mixed/multiracial
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26.0, respectively). Patients presenting with breast tumor
histology of other than invasive ductal carcinoma showed
a 73 % decreased risk of BRCA1 mutations (RP = 0.27;
95 % CI 0.08–0.89; P = 0.03). The prevalence of BRCA1
mutations also varied with tumor grade; women affected
by grade 3 tumors showed the highest risk of carrying a
BRCA1 mutation (Global P < 0.0001). In comparison with
patients diagnosed with non-TNBC, patients affected by
TNBC showed a 390 % higher risk of BRCA1 mutations
(RP = 4.90; 95 % CI 3.09–7.77; P < 0.0001).
The association between TNBC and prevalent BRCA1
mutations was independent of the simultaneous consid-
eration of family history, tumor histology and tumor
grade in a multiple logistic regression model (Table 5).
After adjustment for family history, tumor histology and
tumor grade, patients affected by TNBC showed a 323 %
higher risk of BRCA1 mutations than non-TNBC pa-
tients (RP = 4.23; 95 % CI 2.50–7.14; P < 0.0001).
Discussion
We report a comprehensive analysis of the prevalence of
BRCA1 and BRCA2 germline mutations in Pakistani pa-
tients with TNBC and non-TNBC selected for age of on-
set or family history of breast/ovarian cancer. Results
from our analysis showed that 97 % of all BRCA1/2 mu-
tations in patients with TNBC were found in the BRCA1
gene. The BRCA1 mutation frequency in patients diag-
nosed at early age who did not report a family history of
breast/ovarian cancer, patients diagnosed at early age
irrespective of family history, patients with a family
Table 4 Ratio of the probability of carrying BRCA1/2 mutations in the investigated patients collective based on univariate logistic
regression models
Non-carriers BRCA1 mutation carriers BRCA2 mutation carriers
Variables Level n % n % RP 95 % CI P n % RP 95 % CI P
Agea Cont. 398 100 105 100 0.99 0.97 to 1.01 0.34 20 100 1.01 0.97 to 1.05 0.56
Family phenotype 1 early onset BC
(≤ 30 years)
210 53 21 20 Ref. < 0.0001 6 30 Ref. 0.13
Familial BC 166 42 56 53 3.37 1.96 to 5.80 13 65 2.74 1.02 to 7.37
Familial BC and OC 22 6 28 27 12.72 6.22 to 26.0 1 5 1.59 0.18 to 13.82
Menopausal status Postmenopausal 68 17 10 10 0.51 0.25 to 1.03 0.17 3 15 0.85 0.24 to 3.00 0.97
Premenopausal 329 83 95 90 Ref. 17 85 Ref.
Unknown 1 0 0 0 - 0 0 -
Ethnicity Other 53 13 12 11 0.77 0.39 to 1.50 0.17 5 25 2.45 0.82 to 7.32 0.25
Pathan 60 15 9 9 0.51 0.24 to 1.07 4 20 1.72 0.53 to 0.53
Punjabi 285 72 84 80 Ref. 11 55 Ref.
Histology Ductal 359 90 102 97 Ref. 0.03 18 90 Ref. 0.98
Other 39 10 3 3 0.27 0.08 to 0.89 2 10 1.02 0.23 to 4.57
Tumor size Unknown 80 20 27 26 1.30 0.76 to 2.23 0.73 4 20 0.91 0.28 to 2.97 0.99
pT1 78 20 19 18 0.94 0.52 to 1.70 4 20 0.93 0.28 to 3.05
pT2 181 45 47 45 Ref. 10 50 Ref.
pT3 55 14 11 10 0.77 0.37 to 1.59 2 10 0.66 0.14 to 3.09
pT4 4 1 1 1 0.96 0.11 to 8.82 0 0 -
Tumor grade 1 5 1 0 0 - < 0.0001 0 0 - 0.16
2 116 29 6 6 0.14 0.06 to 0.33 9 45 2.45 0.92 to 6.52
3 253 64 94 90 Ref. 8 40 Ref.
Unknown 24 6 5 5 0.56 0.21 to 1.51 3 15 3.95 0.98 to 15.9
Lymph node status Negative 146 37 47 45 1.49 0.95 to 2.34 0.13 6 30 0.73 0.27 to 1.97 0.83
Positive 232 58 50 48 Ref. 13 65 Ref.
Unknown 20 5 8 8 1.86 0.77 to 4.45 1 5 0.89 0.11 to 7.18
TNBC status Non-TNBC 279 70 34 32 Ref. < 0.0001 18 90 Ref. 0.07
TNBC 119 30 71 68 4.90 3.09 to 7.77 2 10 0.26 0.06 to 1.14
P values marked in bold are statistically significant
BC breast cancer, OC ovarian cancer, Ref. reference, RP ratio of the probability of carrying BRCA1/2 mutations
aMedian age (5th and 95th percentiles) were 30 years (23 to 54) for non-carriers, 30 years (24 to 48) for BRCA1, and 32 years (24 to 53) for BRCA2 mutation carriers
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history of breast cancer, and patients with a family his-
tory of breast and ovarian cancer were approximately 3
to 4 times higher than those observed in non-TNBC pa-
tients. The diagnosis of TNBC independently increased
the risk of carrying a BRCA1/2 mutation. Several studies
have demonstrated the relevance of TNBC status as a
criterion for genetic BRCA testing [7, 13, 15, 22, 26–28];
our study confirms this observation for patients with
TNBC in an Asian population from Pakistan.
Pakistani women were diagnosed with TNBC at a
younger age and with higher grade tumors than non-
TNBC. These findings confirm those from previous
studies conducted among Asian [4, 29], North-American
[30, 31] and African-American patients [31, 32]. A lower
rate of lymph node involvement was observed in Pakistani
patients with TNBC than non-TNBC, which is in line
with previous data from other Asian [29, 33, 34] and
North-American studies [35]. A higher rate was ob-
served in one study among North-Americans [30],
while no difference was observed in a European study
[36]. The discrepant data may be explained by differ-
ences in the study design or the IHC cut-off values for
ER and PR negativity. While data from the study of
Dent and colleagues were based on unselected cases
and a cut-off for ER/PR negativity of < 10 % of tumor
cells staining positive, the Pakistani study participants
were selected for young age or family history of breast/
ovarian cancer and the threshold for negative ER/PR re-
sult was < 1 % of tumor cells staining positive.
In Pakistan, 42 distinct mutations including 40 in
BRCA1 and two in BRCA2 were identified in patients
with TNBC. Of these mutations, 17 mutations (including
five mutations previously identified in Pakistani breast/
ovarian cancer patients) are population-specific as they
were not identified in other populations [23, 37].
Twenty-five recurrent BRCA1/2 mutations (including 18
mutations previously reported in Pakistani breast/ovar-
ian cancer patients) have also been described elsewhere
in the world, indicating that majority of mutations found
in the current study did not differ from those previously
reported in Pakistan or elsewhere.
In most Western studies, the mean age of diagnosis of
TNBC in BRCA1 mutation carriers was significantly
lower than in non-carriers [7, 13, 15]. No difference in
the age of TNBC diagnosis between BRCA1 carriers and
non-carriers was detected in some studies on early-onset
or familial cases from the US [6] and Singapore [18]. In
contrast, Pakistani BRCA1 carriers were two years older
at TNBC diagnosis than non-carriers implying that other
environmental or genetic factors may be operant in
TNBC in this group of women. It is also possible that
the diverse results are due to differences in study design,
selection criteria or ethnicity.
Pakistani women are usually diagnosed with breast
cancer below 40 years of age [38] and often present
with advanced disease [39]. In the current study,
BRCA1 mutations were identified in 14.4 % of early-
onset patients with TNBC, who had no family history
of breast/ovarian cancer. Lower BRCA1 mutations fre-
quencies of 4.3, 7.4 and 8.7 % were observed in other
studies conducted in China, Italy, and the UK, respect-
ively [9, 22, 40]. However, given the small number of
patients with TNBC diagnosed < 30 years of age investi-
gated in these studies (n = ≤ 30), the percentages may
not be truly representative.
In the present study BRCA1/2 mutations were identified
in 58.8 % of patients with TNBC, who reported a family
history of breast/ovarian cancer. In other Asian studies
Table 5 Ratio of the probability of carrying BRCA1/2 mutations in the investigated patients collective relying on multiple logistic
regression model
Non-carriers BRCA1 mutation carriers
Variables Level n % n % RP 95%CI P
Family phenotype 1 early onset BC (≤ 30 years) 210 53 21 20 Ref. < 0.0001
Familial BC 166 42 56 53 4.98 2.77 to 8.97
Familial BC and OC 22 6 28 27 16.22 7.22 to 36.5
Histology Ductal 359 90 102 97 Ref. 0.36
Other 39 10 3 3 0.53 0.13 to 2.08
Tumor grade 1 5 1 0 0 - 0.001
2 116 29 6 6 0.17 0.07 to 0.43
3 253 64 94 90 Ref.
Unknown 24 6 5 5 0.39 0.12 to 1.20
TNBC status Non-TNBC 279 70 34 32 Ref. < 0.0001
TNBC 119 30 71 68 4.23 2.50 to 7.14
P values marked in bold are statistically significant
BC breast cancer, OC ovarian cancer, Ref. reference, RP ratio of the probability of carrying BRCA1/2 mutations
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performed in China, Malaysia, and Korea and also in Cau-
casian studies conducted in Australia, Europe, and the
United States, the mutation frequencies were similar or
lower ranging from 20.8 to 59.5 % [17, 22, 26, 41, 42] and
11.6 to 62 % [7, 8, 10–13, 15], respectively. The varying
mutation frequencies obtained in these studies may be
explained by differences in sample size, mutation detec-
tion assays used, or ethnic origin of study participants.
The low frequency of BRCA2 mutations detected in our
study is in keeping with prior reports and suggests that
BRCA2 may not play an important role in the develop-
ment of early-onset TNBC. With the exception of one
small German study that included 30 patients with TNBC
[11], BRCA2 mutations were less common than BRCA1
mutations in several studies among patients of European
or North-American origin [9, 14, 15, 28] and patients
from Asia [22, 26] including the present one. These data
indicate the tendency for BRCA1 carriers to primarily de-
velop TNBC compared to BRCA2 carriers, which most
commonly develop ER positive breast tumors [43].
Recommendations for genetic BRCA1/2 testing for
patients with TNBC are not universally accepted and
vary between professional societies [13] and studies
[15, 22, 26, 28]. The National Comprehensive Cancer
Network (NCCN) guidelines recommend that women
with TNBC diagnosed before or at age 60 should be
considered for genetic BRCA1/2 testing (NCCN Guide-
lines), while the guidelines of the European Society of
Medical Oncology [44] and the Cancer Institute New
South Wales (https://www.eviq.org.au) recommend test-
ing if TNBC is diagnosed under the ages of 50 and
40 years, respectively. Moreover, testing was suggested
to Mexican patients affected by disease below age 60
[28], below or at age 50 to patients from the UK [27],
China [22] and Malaysia [26], and irrespective of age to
Polish and Australian patients [15]. The high frequency
of BRCA1 mutations in Pakistani patients with a family
history of breast/ovarian cancer diagnosed with TNBC
below or at age 50 and in early-onset patients diag-
nosed before or at age 30 irrespective of family history
suggest that genetic testing should be considered for
these groups of women. Testing women with TNBC di-
agnosed below age 50 has previously been shown to be
a cost-effective strategy [45]. Given the financial burden
these considerations are of particular importance for
developing countries like Pakistan.
Recently, deleterious mutations in 14 known breast
cancer susceptibility genes including BRCA1, BRCA2,
and RAD51C were identified at a frequency of 3.7 % in a
large series of 1,824 patients with TNBC unselected for
family history of breast cancer [7]. As in the study re-
ported by Couch and colleagues, no mutations in the
CHEK2 and TP53 genes were observed in two Pakistani
studies among 374 (including 103 with TNBC) [46] and
105 (including 47 with TNBC) breast/ovarian cancer pa-
tients [47], respectively. Recently, a deleterious mutation
(c.5101C > T) in the FANCM gene was identified in
BRCA1/2-negative familial patients with TNBC from
Finland [48]. This mutation was not detected in a Pakistani
study that included 117 patients with TNBC [49].
There are several limitations of our study. First, we
have screened only patients with TNBC, who were se-
lected for early-age of onset (≤ 30 years) or family history
of breast/ovarian cancer. Hence the selection of high-
risk patients may explain the higher BRCA1/2 mutation
frequency observed in our study compared to those that
evaluated unselected TNBC patients. Secondly, we did
not use BRCA1/2 prediction models. However, given the
previously observed inaccuracy of these algorithms in
predicting risk precisely in Asian populations, limits the
usefulness of these algorithms and warrants further
investigation [50, 51]. Strengths of the present study in-
clude the sample size (N = 523) comprising sufficiently
larger number of early-onset breast cancer (≤ 30 years)
women (n = 303) with TNBC (n = 131) or non-TNBC
(n = 172) compared to studies reported from Asia previ-
ously. Additionally, our study evaluated the complete
coding regions of the BRCA1 and BRCA2 genes that
were comprehensively screened for both, small-range
mutations and large genomic rearrangements. Screen-
ing for both types of mutations has only been reported
in few studies performed previously [10, 26]. Yet an-
other strength was that all data were generated at a sin-
gle institution, therefore no variability was introduced
by using different methods for tumor grading and IHC
analysis and evaluation and the pathologist, who evaluated
the ER, PR, and HER2 status, was blinded to the mutation
status. Finally, the majority of study participants (73.4 %)
were recruited within one year of disease presentation,
which minimizes the likelihood of survival bias.
Conclusions
We found high prevalence and predominance of BRCA1
germline mutations in Pakistani women with TNBC
compared to patients with non-TNBC presenting before
or at age 30 irrespective of family history of breast/ovar-
ian cancer and before or at age 50 with familial breast
cancer or familial breast and ovarian cancer. The associ-
ation between TNBC status and presence of BRCA1
mutations was independent of the simultaneous consid-
eration of family phenotype, tumor histology, and tumor
grade in a multiple logistic regression model. Our data
suggest that TNBC status should be incorporated as a
criterion for genetic BRCA1 testing in Pakistan. Identifi-
cation of individuals with BRCA1 germline mutations
will enable physicians to optimize cancer management
for this high risk phenotype.
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